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1. Introduction  
Viral infections have accompanied humankind from time immemorial. Herpesvirus 
infections, especially those caused by HSV-1 and HSV-2, are among the most common viral 
infections at all. The control and treatment of the virus has changed through history, starting 
with cauterization with hot iron, recommended in ancient Rome, through the most diverse 
herbal treatments and naturopathic remedies including miracle diets. Fundamental change 
in the approach to the whole issue occurred in the second half of the twentieth century with 
discoveries in the field of nucleic acid chemistry. Explanation of nucleic acid structure 
initiated not only enormous interest and the subsequent boom of molecular biology and 
genetics but also the formation of a new field of organic chemistry – chemistry of nucleic 
acid components: nucleosides, nucleotides and oligonucleotides. 
2. Chemically modified nucleosides: First generation of antimetabolites of 
nucleic acids 
It was shown that chemically modified nucleosides or nucleobases can work as 
antimetabolites in the process of nucleic acid metabolism. The word “antimetabolite” 
means, generally, a chemically modified molecule of a natural metabolite able to influence 
some enzyme reactions. Antimetabolites can influence processes in cells (neoplasia) as well 
as processes in cell parasites, e.g. viruses, parasites, and fungi. The first generation of 
antimetabolites is distinguished by a maximum structural resemblance to natural 
metabolites. Many nucleoside or nucleobase analogues from this group were found to be 
effective cytostatics: cytosine arabinoside (Cytarabine, Ara-C), an antileukemic agent used 
for the treatment of acute myeloid leukemia and non-Hodgkin’s lymphoma, 6-
mercaptopurine (Purinethol®, 6-MP) used for the acute lymphoblastic leukemia, 5-
fluorouracil (Efudex® , 5-FU), a thymidylate synthase inhibitor used for the treatment of 
colon, rectal, stomach, skin, breast and pancreatic cancer, and finally, antileukemic agents 5-
azacytidine (Vidaza®) and 2´-deoxy-5-azacytidine (decitabine, Dacogene®), so far the most 
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successful agents approved for therapy of myelodysplastic syndrom. Discoveries of these 
great molecules came in the sixtieth decade of the last century, a period of the beginning of 
great development of nucleoside chemistry. This chemistry was substantially supported by 
the pharmaceutical industry with the intent to finally find an effective medicine against the 
terror of mankind known as cancer. In these times, viral infections were not in the forefront.  
3. Acyclic analogues of nucleosides: The second generation of 
antimetabolites 
The situation had changed by the end of the 1960s and at the beginning of the 1970s. The 
turning point was a large “epidemy” of genital herpes (HSV-2) in the USA, especially 
widespread due to the promiscuous lifestyle of the time. This sexually transmitted disease 
became a common problem for the whole society, and a fast solution got priority. The great 
success came with the synthesis and clinical development of acyclovir (Zovirax) by 
Burroughs-Wellcome. So far this drug is one of the most frequently used drugs against 
HSV-1 and HSV-2 infections. Among others, development of acyclovir resulted in the first 
Nobel Prize targeted to the pharmaceutical industry: in 1988 the Nobel Prize winners for 
medicine were Gertrude B. Elion and Georg Hitchings from the above mentioned company.  
Acyclovir, 9-(2-hydroxyethoxymethyl)guanine, similar to the many other antiherpetic 
agents (penciclovir, ganciclovir and their prodrug forms), belongs to the group of acyclic 
nucleoside analogues, compounds having the sugar furanose ring substituted with a 
polyhydroxylic carbon chain (Fig. 1). These compounds represent the so-called second 
generation of antimetabolites where the structural resemblance to a natural metabolite is 
only present in some basic aspects and the necessary steric arrangement can be formed by 
its subsequent contact with a target metabolic enzyme. 
 
 
Fig. 1. Structures of the most commonly-used antiherpetic drugs from the family of acyclic 
nucleoside analogues 
Fundamental developments in this field were also made in Prague at the Institute of 
Organic Chemistry and Biochemistry in the laboratory of Antonin Holy. His synthetic effort 
and close collaboration with the Belgian virologist Erik De Clercq resulted in many new 
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acyclic nucleoside analogues whose activity against herpes viruses was confirmed. The most 
potent agents were found to be N9-alkyl derivatives of adenine with hydroxyl group(s) on 
the alkyl chain (RS)-3-(adenin-9-yl)-2-hydroxypropanoic acid (AHPA, especially in the form 
of alkyl esters), D-eritadenine and the broad-spectrum antiviral agent (S)-(2,3-
dihydroxypropyl)adenine (DHPA) (De Clercq et al. 1978, De Clercq & Holý 1985, Holý et al. 
1982). Antiviral potency of these adenosine analogues concerns their inhibition of SAM-
dependent methylation reactions via inhibition of S-adenosylhomocysteine (SAH) 
hydrolase. SAH is the product of S-adenosylmethionine (SAM) mediated transmethylation 
reactions and it is itself a feedback inhibitor of these reactions. If SAH hydrolase is inhibited, 
SAH accumulates and thereby all biological processes that require intensive methylations 
are suppressed. One such situation is the maturation of viral mRNA, i.e., 5'-cap formation 
and subsequent blocking virus replication. The most effective inhibitor of SAH hydrolase, 
DHPA became an approved drug for the topical treatment of herpes labialis (HSV-1) in the 
former Czechoslovakia, marketed under the name Duvira® gel (Fig. 2). 
 
 
Fig. 2. Aliphatic analogues of adenosine as inhibitors of SAH hydrolase: DHPA (“Duvira 
gel”), D-eritadenine and AHPA esters 
4. Acyclic nucleoside phosphonates 
The necessary condition for any antimetabolite to be of use in enzyme reactions is its 
phosphorylation. Unfortunately, the direct medical application of phosphates of the 
antimetabolites has no advantage due to their instability. To overcome this problem, in the 
mid-1980s, our Prague team lead by Antonin Holy came up with the revolutionary idea of 
preparation of phosphonomethyl derivatives: compounds stabilized by the introduction of a 
methylene bridge between a phosphonic acid residue and the rest of the molecule. During 
the short time, acyclic nucleoside phosphonates (ANPs) were revealed as compounds with 
an extraordinary broad spectrum of biological activities: antiviral, cytostatic, antiparasitic or 
immunomodulatory. Some of them are commercially available pharmaceuticals effective 
against serious viral infections (cidofovir, adefovir and tenofovir) (Holý, 2003; De Clercq & 
Holý, 2005). Several comprehensive reviews on ANPs as antiviral agents have been 
published recently (Holý & De Clercq, 2010; De Clercq, 2011). 
The mentioned compounds represent three different types of ANPs: HPMP derivatives, i.e. 
(S)-[3-hydroxy-2-(phosphonomethoxy)propyl] derivatives (e.g. HPMPC, cidofovir), PME 
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derivatives, i.e. 2-(phosphonomethoxy)ethyl derivatives (e.g. PMEA, adefovir) and PMP 
derivatives, i.e. (R)-2-(phosphonomethoxy)propyl derivatives (e.g. PMPA, tenofovir).  
4.1 (S)-[3-Hydroxy-2-(phosphonomethoxy)propyl] derivatives (HPMP derivatives) –
Synthesis and activity of HPMPA and its aza/deaza analogues  
HPMP derivatives are active against DNA viruses; the activity is bound always to S 
enantiomers. The first described ANP was 9-(S)-[3-hydroxy-2-
(phosphonomethoxy)propyl]adenine (HPMPA), a compound derived from above 
mentioned DHPA by the introduction of a phosphonomethyl group (De Clercq et al., 1986; 
Holý & Rosenberg, 1987). 
Synthesis of (S)-HPMP derivatives mostly utilizes basically catalyzed nucleophilic opening 
of the oxirane ring in (2S)-2-[(trityloxy]methyl]oxirane or (R)-glycidol butyrate with an 
appropriate nucleobase, e.g. N4-benzoylcytosine, N6-benzoyladenine or 2,6-
bis(benzoylamino)purine (Webb et al., 1988; Brodfuehrer et al., 1994). This reaction proceeds 
regioselectively to N9 position of the purine or N1 position of the pyrimidine base. The 
intermediary formed 2,3-dihydroxypropyl derivatives are subsequently etherified with 
dialkyl (diethyl or diisopropyl) ester of tosyloxymethanephosphonate in the presence of 
sodium hydride. After removal of benzoyl groups and trityl, phosphonic ester groups are 
deprotected by the treatment with bromotrimethylsilane followed by hydrolysis (Holý, 
1993)(Fig. 3). 
 
 
Fig. 3. Synthetic scheme for the preparation of (S)-[3-hydroxy-2-
(phosphonomethoxy)propyl] derivatives of adenine and cytosine (HPMPC and HPMPA) 
from appropriate oxiranes 
Preparation of diisopropyl tosyloxymethanephosphonate consists of the treatment of 
diisopropyl phosphite with paraformaldehyde and triethyl amine followed by tosylation 
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(Holý, 1993). Another possibility for the introduction of a phosphonomethyl ether group 
based on use of diisopropyl bromomethylphosphonate (Göbel et al., 1992) is also 
recommended (Holý, 2005; Oh & Hong, 2008). Most recently, a novel, very efficient and 
environmentally friendly synthesis of diisopropyl bromomethylphosphonate (and other 
dialkylhaloalkylphosphonates in general), has been developed in our Institute using a 
microwave-assisted Michaelis–Arbuzov reaction of dihaloalkanes. Diisopropyl 
bromomethylphosphonate thus can be prepared by reaction of dibromomethane with 
triisopropyl phosphite (Jansa et al., 2011). Syntheses of both agents are depicted in Fig. 4. 
 
 
Fig. 4. Syntheses of reagents for an introduction of a phosphonomethyl residue to the 
molecule of acyclic nucleoside analogues: synthesis of the “Holy´s tosylate”, diisopropyl 
tosyloxymethanephosphonate and the microwave assisted approach to diisopropyl 
bromomethylphosphonate by Jansa  
(S)-HPMPA is a compound with a broad spectrum of anti DNA-virus activities, so far not 
clinically developed. It efficiently inhibits herpesviruses (Andrei et al., 1992) including 
clinical isolates of varicella zoster virus (Andrei et al., 1995), HHV-6 (Reymen et al., 1995) 
and HHV-8 (Neyts & De Clercq, 1997). HHV-6 is one of the recently discovered members of 
the betaherpesviridae family. It is involved in pathogenesis of several diseases including the 
childhood disease exanthema subitum (roseola) (Yamanishi et al. 1988) and 
lymphoproliferative disorders, and it probably takes part in the progression of chronic 
fatigue syndrome (Komaroff, 2006). HHV-6 has also been proposed to be a cofactor in the 
progression of AIDS; high levels of HHV-6 have been found in many AIDS patients. The 
comparative study of effectiveness of diverse kinds of ANP towards HHV-6 revealed, 
besides HPMPA, also several other active (S)-HPMP derivatives: (S)-HPMPC, (S)-cHPMPC, 
(S)-3-deaza-HPMPA, (S)-3-deaza-cHPMPA, (S)-HPMPG, (S)-cHPMPG and (R)-HPMPG, 
their EC50 values ranging from 1 to 11 /µM and their selectivity index ranging from 6 to 30 
(Reymen et al., 1995).  
A special attention is now paid to the investigation of HPMPA prodrugs to improve the 
pharmacokinetic profile of this ANP, especially the development of alkoxyalkyl esters 
(Beadle et al., 2006). It is based on etherification of the appropriate hydroxy derivate with 
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alkoxyalkyl tosyloxymethanephosphonate, a phosphonomethyl residue containing an agent 
having the lipophilic group already preattached. This compound can be prepared in three 
steps from diethyl tosyloxymethanephosphonate: deprotection of ethyl ester groups with 
bromotrimethylsilane, transformation to chloridate by the action of oxalyl chloride, and 
reaction with alkoxyalkanols under basic conditions. The starting material for syntheses of 
HPMPA esters is (S)-9-(3-trityloxy-2-hydroxypropyl)-N6-trityladenine, an intermediate in 
preparation of HPMPA according to Webb’s method (Webb, 1989). 
The whole process is outlined in Figure 5. 
 
 
Fig. 5. Synthesis of alkoxyalkyl ester prodrugs of HPMPA.  
Excellent anti-DNA virus effects were also found at other HPMP derivatives, e.g. 2,6-
diaminopurine counterpart of HPMPA, (S)-HPMPDAP. Recently, a detailed 
investigation of this compound and its ester prodrugs has been performed (Krečmerová 
et al., 2010a). This research, originally targeted to antipoxvirus agents, also selected, 
among others, several candidates with excellent antiherpetic effects. Remarkable broad-
spectrum antiherpetic effects were found at some base modified ANPs (aza/deaza 
analogs). Anti-DNA-viral activity was found especially at (S)-8-aza-HPMPA and (S)-3-
deaza-HPMPA.  
Syntheses of deazapurines, i.e. purines lacking one nitrogen atom in position 1, 3 or 7 and 
their nucleosides and ANPs, were developed by Holý and Dvořáková (Dvořáková et al., 
1993; Dvořáková & Holý, 1993). Activity of (S)-3-deazaHPMPA against herpesviruses is 
comparable to that of the parent compound (S)-HPMPA, especially in case of VZV and 
CMV (Dvořáková et al., 1990). (S)-3-deaza-HPMPA, and its cyclic form, (S)-3-deaza-
cHPMPA are also highly active against HHV-6 infections (Naesens and De Clercq, 2006). 
Evaluation of a series of diverse ANPs for activity against HHV-6 in HSB-2 cells showed 3-
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deaza-HPMPA as a compound with the highest selectivity index (Reymen et al., 1995). In 
spite of all the progress in this topic, there is so far no approved drug for the treatment of 
HHV-6 infections (De Bolle et al., 2005). Moreover there is also another difficulty: no animal 
model for HHV-6 testing. These facts substantiate further intensive exploration of ANPs, 
especially 3-deaza-HPMPA and HPMPA, as potential drug candidates for the treatment of 
HHV-6 infections. 
The synthesis of acyclic nucleotide analogues derived from 8-azapurine was first reported in 
1996 (Holý et al., 1996). In the HPMP series, only (S)-HPMP-8-azaadenine exhibits 
remarkable inhibitory potency to all DNA viruses tested. The best data were found for HSV-
1, TK− HSV, HSV-2, VZV, TK− VZV and vaccinia virus. In particular, exquisitely inhibitory 
effects were found for VZV with MIC 0.2-2 µg/mL. In general, the antiviral potency of 
HPMP-8-azaA is mostly comparable to (S)-HPMPA. Its 2,6-diaminopurine counterpart, (S)-
HPMP-8-aza-DAP is approximately two orders of magnitude less potent of an inhibitor of 
these viruses than HPMP-8-azaA. Other structural types of 8-azapurine ANPs (PMP and (S)-
FPMP derivatives) are not markedly inhibitory to any of the DNA viruses tested. In a series 
of PME derivatives, only PME-8-azaguanine was inhibitory to HSV-1, the thymidine kinase 
(TK-) deficient HSV-1 strains, HSV-2, CMV, both TK+ and TK- VZV strains and vaccinia 
virus (Holý et al., 1996). Structures of the most important anti-DNA viral HPMP derivatives 
are depicted in Fig. 6. 
 
 
Fig. 6. HPMP derivatives: acyclic nucleoside phosphonates with a broad spectrum of 
activities against herpes- and other DNA virus infections 
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4.2 Cidofovir (HPMPC) 
Cidofovir, 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine, is a broad spectrum 
anti DNA virus agent whose spectrum of activities covers all types of human herpesviruses 
[HSV-1, HSV-2, varicella-zoster virus (VZV), Epstein–Barr virus, CMV, HHV-6, HHV-7 and 
HHV-8 — and also thymidine kinase-deficient (TK–) HSV and VZV, and protein kinase-
deficient (PK–) CMV variants], and polyoma-, papilloma-, adeno- and poxviruses. The large 
scale of cidofovir activities has already been a topic of many reviews, e.g. (Hitchcock et al., 
1996; Naesens & De Clercq, 1997; De Clercq, 1998; Naesens et al., 1997). 
Cidofovir was the first acyclic nucleoside phosphonate utilized in clinical practice: in 1996 
this drug was approved by the FDA for the treatment of cytomegalovirus retinitis in AIDS 
patients. The drug is marketed by Gilead Sciences, Inc. under the commercial name 
VistideTM and it is applied to patients in the form of intravenous injections (Fig. 7). CMV 
retinitis is a systemic infection commonly seen in patients suffering from AIDS. It is most 
easily characterized by the cloudiness which can appear in the patient’s retina. If untreated, 
the virus will attack retina cells and develop into lesions. These lesions can eventually lead 
to vision impairment or permanent blindness. Cidofovir suppresses CMV replication by the 
selective inhibition of viral DNA polymerase and therefore prevention of viral replication 
and transcription (Wachsman et al., 1996; Lalezari et al., 1997). A serious side-effect of 
cidofovir (and all other ANPs) is its dose-dependent nephrotoxicity. To surmount this 
problem, cidofovir must be administered in conjunction with probenecid (Bagnis et al., 1999; 
Lacy et al., 1998).  
 
 
Fig. 7. VistideTM - cidofovir injections. The first approved acyclic nucleoside phosphonate in 
clinical practice 
At the present time, cidofovir is also important (off label) particularly for the treatment of 
severe cases of (malignizing) papillomatoses (anogenital, laryngeal)(Calista, 2000; 
Bielamovicz et al., 2002), progressive multifocal leukoencephalopathy caused by JC virus 
(Gasnault et al., 2001), adenovirus infections (Legrand et al., 2001) and some rather obscure 
severe infections caused by poxviruses (vaccinia, orf, molluscum contagiosum) (Bray 
&Wright, 2003). The attractiveness of cidofovir is dramatically enhanced by its supreme 
activity against smallpox virus and related monkey pox virus; both of these highly 
infectious viruses can be easily cultivated and purposely used in a bioterrorist attack. For 
this purpose, the cidofovir prodrug, hexadecyloxypropyl ester CMX001, is currently 
clinically investigated (Chimerix, Inc., California). Moreover, CMX001 is also being 
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developed to treat cytomegalovirus (CMV) and BK virus – potentially deadly diseases for 
immunocompromised patients (www.chimerix-inc.com). 
4.3 5-Azacytosine analogue of cidofovir (HPMP-5-azaC): Higher potency with a lower 
toxicity 
Great success in our search for antiviral compounds came with the discovery of ANPs 
bearing a triazine ring, especially 5-azacytosine as a base component (Krečmerová et al., 
2007a). The 5-azacytosine analogue of cidofovir, i.e. 1-(S)-[3-hydroxy-2-
(phosphonomethoxy)propyl]-5-azacytosine (HPMP-5-azaC), shows antiviral activities 
similar - or in some cases higher - compared to cidofovir, better selectivity, and lower 
toxicity. 
Synthesis of (S)-HPMP-5-azaC can be performed in two different manners. The first 
approach is based on nucleophilic opening of an oxirane ring in (2S)-2-
[(trityloxy]methyl]oxirane with 5-azacytosine under basic conditions, e.g. in a presence of 
sodium hydroxide. The reaction gives regiospecifically the only N-1 substituted product, 1-
[(2S)-2-hydroxy-3-(triphenylmethoxy)propyl]-5-azacytosine), in excellent yield. Its further 
treatment with diisopropyl tosyloxymethylphosphonate in the presence of excess sodium 
hydride in N,N-dimethylformamide gave fully protected phosphonate ester, which was 
subsequently treated with bromotrimethylsilane followed by hydrolysis. This process leads 
simultaneously to a removal of trityl group and phosphonate protecting diisopropyl ester 
groups under formation of the final HPMP-5-azaC (Fig. 8). 
 
 
Fig. 8. Synthesis of (S)-HPMP-5-azaC from (2S)-2-[(trityloxy)methyl]oxirane. The stepwise 
approach 
The second approach is based on alkylation of 5-azacytosine with an appropriate chiral 
synthon, i.e. the whole aliphatic part activated with a suitable leaving group, usually tosyl 
or halogen (Fig. 9). Preparation of “(S)-HPMP synthon”, i.e. diisopropyl ester of (1S)-[2-
hydroxy-1-tosyloxymethyl)ethoxy]methylphosphonate followed the protocol originally 
developed for its racemic form (Hocek et al., 1996). Also in this case, (2S)-2-
[(trityloxy]methyl]oxirane was selected as a starting material. The oxirane ring was first 
opened by nucleophilic reaction with sodium benzylate to give (2S)-1-benzyloxy-3-
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trityloxypropan-2-ol. The next steps are introduction of a phosphonomethyl residue using 
diisopropyl bromomethanephosphonate, removal of the trityl group with acetic acid, 
tosylation, and the final deprotection of benzyl group by catalytic hydrogenation. Removal 
of benzyl group just in this step, i.e. still in a stage of the synthon is necessary. Its removal in 
some of the following steps would not be possible due to a sensitivity of 5-azacytosine 
towards catalytic hydrogenation leading to 5,6-dihydro-5-azacytosine derivatives. 
Diisopropyl (1S)-[2-hydroxy-1-tosyloxymethyl)ethoxy]methylphosphonate (HPMP-
synthon) was used for the final condensation with a sodium salt of 5-azacytosine. This 
condensation proceeds exclusively to form the desired N-1 isomer, i.e. diisopropyl ester of 
HPMP-5-azaC, accompanied by N-3 and O-isomers in a small amount only. This reaction 
was revealed as an advantageous approach to HPMP-5-azaC, especially for its larger-scale 
syntheses (Krečmerová et al., 2010b). The final deprotection of ester groups was performed 
by the standard procedure with bromotrimethylsilane, followed by hydrolysis. 
 
 
Fig. 9. Synthesis of (S)-HPMP-5-azaC by the synthon approach 
HPMP-5-azaC showed potent and selective activity against several DNA viruses, including 
different herpesviruses (HSV-1, HSV-2, VZV, HCMV and HHV-6), adenovirus (Ad2) and 
poxvirus (vaccinia virus) with 50% effective concentration (EC50) values of 0.71µg/mL for 
Ad2, 2.56 µg/mL for vaccinia virus and 0.02-0.6 µg/mL for herpesviruses. The antiviral 
activity of HPMP-5-azaC was comparable to cidofovir against HSV-1, HSV-2 and vaccinia 
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virus, or 2 to 7 times more active against VZV, HCMV, HHV-6 and Ad2. HPMP-5-azaC 
proved to be 2 times less cytotoxic for HEL cells than (S)-HPMPC but 2-fold more toxic for 
human T-lymphoblast HSB-2 cells. For all these DNA viruses, HPMP-5-azaC showed a 2- to 
16-times higher antiviral selectivity index (ratio of CC50 to EC50) than (S)-HPMPC (cidofovir) 
(Krečmerová et al., 2007a). 
In contrast to cidofovir, HPMP-5-azaC has more complicated metabolic profile, and, similar 
to other N-1 substituted 5-azacytosine derivatives (riboside, 2´-deoxyriboside, arabinoside), 
it decomposes in alkaline conditions (Dračínský et al., 2008). The first step is a reversible 
ring opening of the sym-triazine to the N-formylguanidine derivative which can close back 
to the cyclic structure. This hydrolytic reaction is slow and reaches equilibrium within 
several days. However, the reversible ring-opening hydrolysis is accompanied by 
irreversible deformylation reaction of the intermediary formyl derivative that gives rise to 
antivirally inactive 2-{[(2S)-3-hydroxy-2-(phosphonomethoxy)propyl]carbamoylguanidine. 
Among these decomposition products (Fig. 10), the N-formylguanidine derivative, which 
can close back to the cyclic structure, showed activity with equivalent EC50 values to those 
obtained for the original compound HPMP-5-azaC (VZVand HCMV) or at 3- to 25-fold 
higher EC50’s for HSV-1, HSV-2, HHV-6, Ad2 and vaccinia virus. In contrast, the final 
decomposition product, the carbamoylguanidine derivative, is antivirally inactive 
(Krečmerová et al., 2007a). 
 
 
Fig. 10. The course of decomposition of (S)-HPMP-5-azaC in alkaline conditions 
Investigation of the intracellular metabolism of HPMP-5-azaC revealed its phosphorylation 
to mono- and diphosphate (60 fold higher then cidofovir) and deaminated uracil product 
(HPMP-5-azaU) as a minor component (6%). HPMP-5-azaC also showed about 45-fold 
higher incorporation into cellular DNA than cidofovir. In general, HPMP-5-azaC has a 
favorable metabolic profile that is characterized by low sensitivity to catabolic deamination 
and high efficiency for phosphorylation and DNA incorporation (Naesens et al., 2008).  
Discovery of the unique antiviral activity of HPMP-5-azaC resulted in the necessity to also 
prepare some kinds of prodrugs: the cyclic form of 1-(S)-[3-hydroxy-2-
(phosphonomethoxy)propyl]-5-azacytosine (cHPMP-5-azaC) and its esters. Transformation 
of HPMP-5-azaC to its cyclic form was realized by the action of dicyclohexylcarbodiimidide 
(DCC) and N,N,-dicyclohexyl-4-morpholinocarboxamidine. To assess the role of ester 
structure in antiviral activity, four diverse ester types were synthesized: alkyl (octadecyl), 
alkenyl (erucyl, i.e. (Z)-docos-13-enyl), pivaloyloxymethyl (POM) and alkoxyalkyl (2-
(hexadecyloxy)ethyl, HDE). The most successful esterification method was the reaction of 
tetrabutylammonium salt of cHPMP-5-azaC with alkyl bromides or with chloromethyl 
pivalate, respectively (Fig. 11) (Krečmerová et al., 2007b).  
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Fig. 11. Synthesis of ester prodrugs derived from the cyclic (S)-HPMP-5-azaC 
cHPMP-5-azaC was able to inhibit the replication of poxviruses (vaccinia virus), and 
different herpesviruses, including herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), 
thymidine kinase-deficient HSV-1 [acyclovir resistant (ACVr)], varicella-zoster virus (VZV), 
human cytomegalovirus (HCMV) and human herpesvirus 6 (HHV-6) with EC50 values in 
the range of 0.06 to 3.1 µg/ml. cHPMP-5-azaC did not affect cell morphology or cell growth 
(measured on HEL cells). This resulted in selectivity indices (ratio of CC50 to EC50) varying 
from >47 (vaccinia virus) to >1500 (HCMV). The potency of the new triazine analogues 
HPMP-5-azaC and cHPMP-5-azaC was comparable to that of HPMPC and cHPMPC; 
however, HPMP-5-azaC and cHPMP-5-azaC proved to be approximately 2 times less 
cytostatic for HEL cells than HPMPC and cHPMPC, resulting in a superior selectivity.  
When the different ester prodrugs, i.e. octadecyl, (erucyl), alkoxyalkyl (HDE) and 
pivaloyloxymethyl (POM), were evaluated, the HDE emerged as the most active one, with 
EC50 values in the range of 0.003 to 0.008 µg/mL for HSV, ≤0.0008 to ≤.0014 µg/mL for VZV, 
≤0.00014 to ≤0.00038 µg/mL (HCMV), 0.008 to 0.037 µg/mL for HHV-6 and 0.037 µg/mL for 
vaccinia virus. This resulted in 58- (vaccinia virus), 100- (mean for HSV strains), 123- (mean 
for VZV strains) to 250-fold (mean for HCMV strain) increase in antiviral activity when 
compared to cHPMP-5-azaC. Not only an improvement in the antiviral activity, but also an 
increase in selectivity, was observed for HDE-cHPMP-5-azaC. Thus, selectivity indices for 
HDE-cHPMP-5-azaC were found 43 (HHV-6A), 70 (HHV-6B), 173 (vaccinia virus), 1160 
(HSV), ≥5800 (VZV) and ≥24600 (HCMV), as compared to 74 (HHV-6A), 11 (HHV-6B), >47 
(vaccinia virus), >180 (HSV), >740 (VZV) and >1540 (HCMV) for the free cHPMP-5-azaC.  
Although a marked increase in antiviral potency was noted for the octadecyl ester compared 
to free cHPMP-5-azaC against HCMV (EC50 = 0.0014-0.0037 µg/mL), only a slight increase 
in activity against VZV or a decrease in potency against HSV was observed. Despite the fact 
www.intechopen.com
Nucleoside and Nucleotide Analogues for the Treatment of Herpesvirus Infections:  
Current Stage and New Prospects in the Field of Acyclic Nucleoside Phosphonates 
 
257 
that the octadecyl ester did not affect cell growth up to a concentration of 100 µg/mL, it 
produced an alteration of cell morphology at a concentration ≥20 µg/mL.  
The esterification of cHPMP-5-azaC to the erucyl prodrug resulted in a loss of activity 
against vaccinia virus and no improvement or slight decrease in activity against HSV and 
VZV. The pivaloyloxymethyl ester has a good potency against HCMV (EC50 <0.032 µg/mL), 
but generally, its EC50 values are equivalent to those of the free cHPMP-5-azaC.  
Progress in the investigation of HPMP-5-azaC and its derivatives is currently still under 
way. The compound finished its preclinical stage of investigation; its eventual clinical 
development can be supported by the very promising results in in vivo models of poxvirus 
and herpesvirus infections, as well as by our recent progress on the development of new 
types of ester prodrugs. These results can substantially improve oral bioavailability of the 
compound and pharmacological properties in general. HPMP-5-azaC also has a potent 
activity and selectivity against polyomaviruses: murine polyoma virus, primate simian virus 
40 strains and BK virus in human primary renal cells. These findings highlight HPMP-5-
azaC and its derivatives as potential drug candidates against polyomavirus associated 
nephropathies in kidney transplant patients, a diagnosis so far with no FDA approved 
treatment (Topalis et al., 2011). 
4.4 (S)-HPMPDAP and its prodrugs – Synthesis of ester prodrugs in HPMP series 
In our recent collaborative project with the Rega Institute in Belgium, we have performed a very 
detailed study of the antiviral efficacy of (S)-HPMPDAP against various DNA viruses, 
including poxviruses [i.e. vaccinia virus (VACV)] and herpesviruses [i.e. herpes simplex virus 
type 1 (HSV-1)] and type 2 (HSV-2), thymidine kinase-deficient HSV-1 (acyclovir-resistant, 
ACVr), varicella-zoster virus (VZV), human cytomegalovirus (HCMV), and human herpesvirus 
6 (HHV-6)]. In the case of HSV-1, HSV-1 ACVr, HSV-2, and VZV, EC50 values for (S)-
HPMPDAP and its cyclic form and (S)-HPMPC were similar. In contrast, (S)-HPMPC was more 
inhibitory towards HCMV than (S)-HPMPDAP or its cyclic form (Krečmerová et al., 2010a).  
(S)-HPMPDAP, similar to other acyclic nucleoside phosphonates, represents a compound 
with a low bioavailability caused by the high polarity of a phosphonic group; its utilization 
in a prodrug form is thus highly desirable (Fig. 12). 
ANPs lacking a free hydroxyl group in a side chain (PME and PMP derivatives) are mostly 
developed in a form of neutral bis(esters) or bis(amidates). In contrast to them, no prodrugs 
are commercially available in the case of HPMP derivatives, compounds having a free 
hydroxyl group in a side chain. Synthesis of their diesters is problematic due to a formation 
of corresponding cyclic phosphonates. So far, the most promising prodrugs seem to be 
alkoxyalkyl monoesters (Kern et al., 2002). One representative of this group, 
hexadecyloxypropyl ester of cidofovir (CMX001) is currently developed as antipox virus 
agent in clinical Phase II (www.chimerix-inc.com). 
The alkoxyalkyl ester prodrugs of (S)-HPMPDAP, i.e. hexadecyloxypropyl, 
octadecyloxyethyl and hexadecyloxyethyl derivatives, emerged as the most potent and 
selective compounds against VACV with EC50 values consistently in the range of 0.00074-
0.0012 µM. Although the alkoxyalkyl ester prodrugs proved more toxic than the parent 
compound (S)-HPMPDAP, either for HEL cell morphology or HEL cell growth, they were 
more selective than (S)-HPMPDAP, with selectivity indices [ratio = CC50 / EC50] higher than 
10,000 compared to >625 for (S)-HPMPDAP. The alkoxyalkyl ester prodrugs of the cyclic 
form of (S)-HPMPDAP (both cis and trans isomers) inhibited VACV replication with EC50 
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values that were 10-fold (ODE ester, trans), 48-fold (HDP ester), 100-fold (ODE ester cis) and 
100- to 200-fold (HDE, cis and trans) lower than that of cyclic(S)-HPMPDAP. The EC50 values 
obtained for the alkoxyalkyl ester prodrugs of cyclic(S)-HPMPDAP were about 3- to 70-fold 
higher against vaccinia virus than the corresponding monoester prodrugs of (S)-HPMPDAP, 
and they had selectivity indices of 1,200 to 8,000.  
The alkoxyalkyl ester prodrugs of (S)-HPMPDAP and its cyclic form also proved 
remarkably potent and selective against HSV-1, HSV-2, HSV-1 ACVr, VZV, and HCMV, 
with EC50 values in the range of 0.007-0.0008 µM. Lower activities of the alkoxyalkyl ester 
prodrugs of cyclic(S)-HPMPDAP than of the corresponding alkoxyalkyl ester prodrugs of 
(S)-HPMPDAP were also observed against HSV and VZV. The alkoxyalkyl ester prodrugs 
also showed potent activity against HCMV, with EC50 values at least 225-fold lower than 
those for the corresponding parent compound. The alkoxyalkyl ester prodrugs proved 
rather toxic against the lymphoblast HSB-2 cells; and the only compounds, the HDP 
derivatives of (S)-HPMPDAP and cyclic(S)-HPMPDAP, respectively, showed selective 
activity against HHV-6 at non-toxic concentrations.  
Although the POM esters (both monoester and cis and trans isomers of the cyclic form), 
2,2,2-(trifluoro)ethyl esters, the butylsalicylyl derivatives, and prodrugs based on 
peptidomimetics proved less active than the alkoxyalkyl ester prodrugs, they appeared to be 
less cytotoxic and cytostatic. The POM derivate of cyclic(S)-HPMPDAP, either the 
diastereoisomeric mixture or the trans isomer, was able to inhibit VACV replication with 
EC50 values similar to those observed with the parent compounds, while 2,2,2-
(trifluoro)ethyl esters, the butylsalicylyl derivatives, and peptidomimetic esters showed EC50 
values 4- to 16-fold higher than the parent compounds. The POM, 2,2,2-(trifluoro)ethyl, 
butylsalicylyl derivatives, and prodrugs based on peptidomimetics also proved active 
against HSV, VZV, and HCMV, with EC50’s similar or 10-fold higher than those of the 
parent drugs. Both types of POM esters (cyclic and monoester) also displayed potent and 
selective activity against HHV-6. The EC50 values and the selectivity indices for these 
compounds against HHV-6 were equivalent to those observed for (S)-HPMPDAP. 
As mentioned above, despite the great experience in development of phosphonate and 
phosphate prodrugs, preparation of prodrugs in HPMP series remained long problematic 
(Hecker & Erion, 2008). In our recent work on HPMPDAP prodrugs, we managed to work 
out conditions for the selective transformation of a free HPMP derivative to the 
corresponding POM monoester in one reaction step. Reaction can be achieved by the action 
of chloromethyl pivalate in DMF in the presence of N,N,-dicyclohexyl-4-
morpholinecarboxamidine; the reaction conditions were optimized so that no cyclization or 
formation of decomposition products occurred (Krečmerová et al., 2010a). This procedure 
was also found generally useful for preparation of other POM HPMP monoesters (e.g. 
HPMPC, HPMP-5-azaC, HPMPA). Preparation of cyclic HPMP POM esters can be 
performed by the action of chloromethyl pivalate and a tetrabutyl ammonium salt of an 
appropriate cyclic phosphonate (Fig. 13). 
Besides procedures based on alkylation of tetrabutylammonium salt of the cyclic 
phosphonate, we focused on development of new approaches based on activation of a 
phosphonic acid residue with hexafluorophosphate coupling agents - PyBOP, PyBroP or 
HATU. Such reagents are currently used as coupling agents, especially in peptide chemistry 
(Han & Kim, 2004). This approach proved successful, e.g. in preparation of 2,2,2-
(trifluoro)ethyl esters, so far known only in PME series (Sekyia et al., 2002; Kamiya et al., 
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2002). Also in this case, the desired 2,2,2-(trifluoroethyl) monoester could be prepared from 
a free phosphonic acid (HPMPDAP) in one reaction step without any protection (Fig. 14).  
 
 
Fig. 12. Structurally diverse types of (S)-HPMPDAP prodrugs prepared for investigation of 
their anti-poxvirus and anti-herpesvirus activities 
 
 
Fig. 13. Synthesis of POM esters of (S)-HPMPDAP. The reactions were successfully applied 
also for HPMPC, HPMP-5-azaC and HPMPA.  
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Fig. 14. Structures of some hexafluorophosphate coupling agents and their utilization in 
synthesis of 2,2,2-(trifluoro)ethyl ester prodrugs of (S)-HPMPDAP 
Also, synthesis of other types of HPMP prodrugs can be simplified using the above-
mentioned coupling agents, e.g. synthesis of salicylyl esters or peptidomimetic prodrugs 
((Krečmerová et al., 2010a; Peterson et al., 2011).  
4.5 PME derivatives, open-ring analogues and other structures 
In a (phosphonomethoxy)ethyl (PME) series, special attention should be paid to the adenine 
derivative 9-(2-phosphonomethoxyethyl)adenine (PMEA), 2,6-diaminopurine derivative 
(PMEDAP) and its N6-substituted analogues. The activity of PME-derivatives against DNA 
viruses is generally lower compared to their counterparts in the HPMP-series (Holý, 2003). 
The most active compound is 9-(2-phosphonomethoxyethyl)-2,6-diaminopurine (PMEDAP). 
PME-derivatives of adenine and 2,6-diaminopurine reveal remarkable activity against HHV-
6 in vitro (Reymen et al., 1995; Manichanh et al., 2000). PMEDAP is also highly effective 
against HCMV; it inhibits the expression of HCMV late antigens.  
N6-substitutution on the 6-amino group of PMEDAP by one or two alkyl, aryl or cycloalkyl 
group lead to the compounds with pronounced activities against herpesviruses, especially 
cytomegalovirus, VZV and EBV (Snoeck et al., 1997; Meerbach et al., 1998). Despite its 
excellent antiviral parameters, PMEDAP has never been systematically investigated as an 
antiviral agent. Its main clinical potential lies in its cytostatic effects. 
During the past decade, we have also systematically investigated a novel group of base 
modified ANP, the “open-ring” analogues (Fig. 15). They are characterized by an aliphatic 
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chain (PME-, PMP and/or HPMP-group) linked to the position 6 of 2,4-diaminopyrimidine 
(DAPy) via the oxygen atom. These compounds can be thought of as mimics of the 
appropriate 2,6-diaminopurine derivatives with an open imidazole ring. Their antiviral 
activity is essentially identical to that of the parent compounds, including their enantiomeric 
specificity (De Clercq et al., 2005). The 6-[2-(phosphonomethoxy)ethoxy]-2,4-
diaminopyrimidine (PMEO-DAPy) and its 5-substituted derivatives offer antiviral potential 
similar to adefovir, mostly against retroviruses and HBV. (R)-HPMPO-DAPy has antiviral 
potential similar to cidofovir (herpes-, adeno, pox-, polyoma and papilllomaviruses) (De 
Clercq, 2011). 
 
 
Fig. 15. Structures of selected (phosphonomethoxy)ethyl (PME) derivatives and “open-ring” 
analogues 
5. Animal herpesviruses  
The last chapter should be devoted to a special part of virology – animal viruses (Giguère et 
al., 2006). Their study is important from a veterinary viewpoint in general but many of them 
can cause diseases which are economically devastating. There is a wide variety of different 
herpesviruses with different biological characteristics. In animals the most important 
herpesviruses belong to the Alphaherpesviridae.  
Pseudorabies virus causing Aujeszky's disease in pigs is now extensively studied as a model 
for basic processes during lytic herpesvirus infection and for unravelling molecular 
mechanisms of herpesvirus neurotropism. The disease is caused by porcine herpesvirus 1, 
also called pseudorabies virus (PRV) or suid herpesvirus-1 (SHV-1). PRV is considered to be 
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the most economically important viral disease of swine in areas where hog cholera has been 
eradicated (“Hog cholera” is an alternative name of classical swine fewer (CSF), an 
infectious disease caused by a pestivirus CSFV from the family Flaviviridae) (Fenner et al., 
1993). Pseudorabies is endemic in most parts of the world. Pigs are the only natural host for 
the Aujeszky's virus. Clinical signs in pigs vary depending on the age of the pigs involved. 
In neonatal pigs, the incubation period is 2-4 days, and signs of central nervous system 
disease (shivering, inco-ordination and hind leg weakness) are seen. In weaned pigs, 
respiratory disease is the predominant problem. Sneezing, coughing and laboured breathing 
is accompanied by fever and weight loss. Mortality rates tend to decrease as the age of the 
affected pigs rises. Clinical signs can be present for 6-10 days. In uncomplicated cases, the 
animals often recover. (Lee & Wilson, 1979). Other domestic and wild mammals, such as 
cattle, sheep, goats, cats, dogs and raccoons (Thawley & Wright, 1982), are also susceptible 
to this virus. For these hosts, the disease is usually fatal and no effective treatment is 
available. The main symptoms in dogs include intense itching, jaw and pharyngeal 
paralysis, howling, and death. In cats, the disease is so rapidly fatal that there are usually no 
symptoms. Death usually occurs within 48 hours. Vaccines are available only for swine. 
Bovine herpesvirus 1 causes several diseases in cattle: infectious bovine rhinotracheitis 
(IBR), infectious pustular vulvovaginitis (IPV), balanoposthitis, conjunctivitis, abortion, 
encephalomyelitis, and mastitis. The respiratory form is most common. The viral infection 
itself is not life-threatening but predisposes to secondary bacterial pneumonia, which may 
result in death. (Jones & Chowdhury, 2007, 2010). Immunization with modified live or 
inactivated virus vaccine generally provides adequate protection against clinical disease. 
The avian herpesvirus 1 (also called Gallid herpesvirus 1, GaHV-1) is phylogenetically 
different from both abovementioned viruses and serves to underline similarity and diversity 
within the Alphaherpesviridae. The virus is a causative agent of laryngotracheitis in poultry. 
(Hidalgo, 2003). A vaccine is available but it does not prevent latent infections. 
Herpesvirus infections are one of the main reasons of animal abortions (Chénier et al., 2004; 
Smith, 1997). Abortion or neonatal diseases may follow infection with not only alpha-
herpesviruses but also beta and gamma-herpesviruses. The alpha-herpesvirus, equine 
herpesvirus-1 (EHV-1), causes single or epizootic abortions or neonatal deaths in horses, and 
the closely related virus EHV-4 causes sporadic equine abortions. In cattle, the alpha-
herpesviruses, bovine herpesvirus-1 (infectious bovine rhinotracheitis virus) and bovine 
herpesvirus-5 (bovine encephalitis virus), and a gamma-herpesvirus, bovine herpesvirus-4, 
have all been implicated as causes of abortion. In pigs, suid herpesvirus-1 (SHV-1: 
pseudorabies virus), an alpha-herpesvirus, and SHV-2 (porcine cytomegalovirus), a beta-
herpesvirus, each cause abortion or neonatal piglet losses. Caprine herpesvirus-1, canine 
herpesvirus and feline herpesvirus-1, all alpha-herpesviruses, cause abortions or neonatal 
deaths in goats, dogs and cats, respectively.  
5.1 Investigation of antiviral activity of acyclic nucleoside phosphonates against 
animal herpesviruses 
Many years of lasting research on acyclic nucleoside phosphonates (ANPs) as exceptional 
drugs and/or drug candidates against human viral infections gave an impetus for their 
study as antivirals in veterinary medicine. The well- researched candidate is cidofovir, 
active against equine herpes virus type 1, bovine herpesvirus type 1, feline herpesvirus type 
1 and caprine herpesvirus type 1. Remarkable effects against animal herpesviruses were also 
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observed at HPMPA and finally at PMEDAP, 9-(phosphonomethoxypropyl)-2,6-
diaminopurine, a compound mostly investigated for its cytostatic effects. 
Recently, several extensive studies have been paid to the treatment of caprine herpesvirus 1 
(CpHV-1) infections by cidofovir.  
Caprine herpesvirus 1 (CpHV-1) is responsible for recidivous genital disease in adult goats, 
characterized by confluent vesicles evolving to ulcers and crusts on the vulvar rima and 
vaginal mucosa (Tempesta et al., 1999). Several biological similarities exist between CpHV-1 
and the human genital herpesvirus type 2, such as the preferential tropism for the genital 
tract, the vesicular ulcerative nature of the topical lesions, and the tendency to become latent 
in the sacral ganglia (Lafferty et al., 1987; Tempesta et al., 1999). This makes the genital 
CpHV-1 infection of goats a reliable animal model for comparative studies. In described 
experiments, goats were infected experimentally by the vaginal route with CpHV-1 and 
then treated topically at different time intervalas after infection. The administration of 1% 
cidofovir cream onto vaginal mucosa was able to prevent the onset of genital lesions and to 
decrease significantly the titers of the virus shed by the infected animals, notably in the 
groups treated shortly after infection (24 and 48 h). The efficacy of cidofovir against caprine 
herpesvirus infection was higher when the treatment was started shortly after infection than 
when lesions were already present and advanced (Tempesta et al., 2007, 2008). Concerning 
other drugs effective against CpHV-1, the attention of researchers has been focused in recent 
years also on the study of acyclovir and ganciclovir. 
In horses, two herpesvirus infections mostly occur: equine herpesviruses 1 (EHV-1) and 4 
(EHV-4) (Patel & Heldens, 2005). Although both viruses may cause febrile 
rhinopneumonitis, EHV-1 is the main cause of abortions, paresis and neonatal foal deaths. 
The lesion central to these three conditions is necrotising vasculitis and thrombosis resulting 
from lytic infection of endothelial cells lining blood capillaries. The initiation of infection in 
these lesions is likely to be by reactivated EHV-1 from latently infected leukocytes. 
However, host factors responsible for reactivation remain poorly understood. Although 
vaccines are available, they are not fully protective and outbreaks of disease may occur in 
vaccinated herds. Therefore, there is an urgent need for effective antiviral treatment. 
It was found that ganciclovir is the most potent compound and therefore a valuable 
candidate for the treatment.  
Ganciclovir displays the best overall activity against EHV-1infection in vitro, without 
affecting cell viability. However, due to the high cost price, there is no direct clinical 
application possible. Therefore, acyclovir seems to be a more valuable candidate for 
antiviral therapy against EHV-1. As acyclovir has been patented since 1997 and generic 
alternatives are available, it seems attractive to use this drug for the treatment of horses 
during an outbreak (Wilkins et al., 2005). However, the bioavailability of orally 
administered acyclovir is a serious restriction (Bentz al., 2006). Bioavailability of only 2.8%, 
resulting in low plasma concentrations, is inadequate to expect any clinically relevant 
antiviral efficacy. The oral prodrug of acyclovir, valacyclovir seems to be more effective due 
to its higher bioavailability (Ormrod & Goa, 2000). Recently, a large study comparing the 
effect of several antiviral drugs - acyclovir, ganciclovir, cidofovir, adefovir, 9-(2-
phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) and foscarnet against three 
abortigenic (94P247, 97P70 and 99P96) and three neuropathogenic isolates (97P82, 99P136 
and 03P37) of EHV-1 was performed (Garré, B. et al., 2007). Ganciclovir was most potent in 
reducing plaque number, followed by PMEDAP and acyclovir. Adefovir and cidofovir were 
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less effective and foscarnet was the least effective compound. There were no differences 
detected for acyclovir, ganciclovir, adefovir and PMEDAP between the abortigenic and 
neuropathogenic isolates. Although cidofovir is not highly efficient in reducing plaque 
number, it is able to significantly reduce plaque size at very low concentrations. Cidofovir 
was 40-fold more effective in reducing plaque size than in reducing plaque number (Garré, 
B. et al., 2007). 
A similar comparative study was also performed for feline herpesvirus. Feline herpesvirus 1 
(FHV-1) is a common cause of respiratory and ocular disease in cats. Especially in young 
kittens that have not yet reached the age of vaccination, but have already lost maternal 
immunity, severe disease may occur. In the study, the efficacy of six antiviral drugs - 
acyclovir, ganciclovir, cidofovir, foscarnet, adefovir and 9-(2-phosphonylmethoxyethyl)-2, 6-
diaminopurine (PMEDAP), against FHV-1 was compared in Crandell-Rees feline kidney 
(CRFK) cells using reduction in plaque number and plaque size as parameters. The capacity 
to reduce the number of plaques was most pronounced for ganciclovir, PMEDAP and 
cidofovir. All antiviral drugs were able to significantly reduce plaque size when compared 
with the untreated control. As observed for the reduction in plaque number, ganciclovir, 
PMEDAP and cidofovir were most potent in reducing plaque size. Adefovir and foscarnet 
were intermediately potent. The most remarkable effect was observed for cidofovir and 
ganciclovir. None of the products were toxic for CRFK cells at antiviral concentrations (van 
der Meulen, K. et al., 2006). 
6. Conclusion 
For a long time, viral infections remained a major medical problem worldwide due to a lack 
of therapy, prevention, or vaccination strategy, and also due to the rapid development of 
resistance. Four decades of intensive research in the field of nucleic acid component 
chemistry brought the fundamental changes in the treatment of most viral infections. 
Discovery of acyclic nucleoside phosphonates and their systematic investigation resulted in 
marketed drugs effective so far against fatal infections (AIDS, HBV, CMV infections in 
immunocompromised patients, etc.). The fundamental research in the field resulted in many 
excellent active structures so far waiting for clinical investigation, e.g. “open-ring” 
analogues, HPMP-5-azaC, HPMPDAP, and many other structures described in the text. 
Investigation of these compounds still remains a significant challenge for the 
pharmaceutical industry.  
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